-$0.35 Earnings Per Share Expected for Tetraphase Pharmaceuticals Inc (TTPH) This Quarter

Equities research analysts forecast that Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) will report earnings of ($0.35) per share for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Tetraphase Pharmaceuticals’ earnings, with estimates ranging from ($0.40) to ($0.28). Tetraphase Pharmaceuticals reported earnings of ($0.63) per share in the same quarter last year, which suggests a positive year over year growth rate of 44.4%. The business is scheduled to announce its next earnings results on Thursday, November 1st.

According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full year earnings of ($1.40) per share for the current fiscal year, with EPS estimates ranging from ($1.82) to ($1.05). For the next financial year, analysts forecast that the business will report earnings of ($1.15) per share, with EPS estimates ranging from ($2.00) to ($0.77). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Tetraphase Pharmaceuticals.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.18. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%. The business had revenue of $11.58 million for the quarter, compared to the consensus estimate of $2.23 million.

TTPH has been the topic of several recent research reports. B. Riley upped their price objective on Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, August 28th. WBB Securities upgraded Tetraphase Pharmaceuticals from a “speculative buy” rating to a “buy” rating and set a $7.00 price objective on the stock in a research report on Thursday, September 6th. Zacks Investment Research downgraded Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. ValuEngine downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, July 30th. Finally, HC Wainwright upped their price objective on Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, August 28th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $6.16.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TTPH. Flagship Harbor Advisors LLC purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth about $104,000. Cubist Systematic Strategies LLC lifted its position in Tetraphase Pharmaceuticals by 232.1% during the second quarter. Cubist Systematic Strategies LLC now owns 35,537 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 24,837 shares during the period. Canada Pension Plan Investment Board purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth about $179,000. Dynamic Technology Lab Private Ltd lifted its position in Tetraphase Pharmaceuticals by 322.1% during the first quarter. Dynamic Technology Lab Private Ltd now owns 76,108 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 58,079 shares during the period. Finally, Royce & Associates LP purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth about $556,000. Hedge funds and other institutional investors own 40.93% of the company’s stock.

Shares of NASDAQ:TTPH opened at $2.43 on Thursday. Tetraphase Pharmaceuticals has a 52-week low of $2.05 and a 52-week high of $6.97. The firm has a market capitalization of $145.89 million, a PE ratio of -0.92 and a beta of 2.57.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Recommended Story: How to use beta for portfolio diversification

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply